Hos HIV- 1- inficerede patienter (n = 6) var indinavirs og efavirenz 'farmakokinetik generelt sammenlignelig med data fra ikke- inficerede frivillige.
In HIV-1 infected patients (n = 6), the pharmacokinetics of indinavir and efavirenz were generally comparable to these uninfected volunteer data.